- Home
- HPS vs KURA Comparison
HPS vs KURA Comparison
Compare HPS & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPS
- KURA
- Stock Information
- Founded
- HPS 2003
- KURA 2014
- Country
- HPS United States
- KURA United States
- Employees
- HPS N/A
- KURA N/A
- Industry
- HPS Investment Managers
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HPS Finance
- KURA Health Care
- Exchange
- HPS Nasdaq
- KURA Nasdaq
- Market Cap
- HPS 475.4M
- KURA 561.9M
- IPO Year
- HPS N/A
- KURA N/A
- Fundamental
- Price
- HPS $14.71
- KURA $7.86
- Analyst Decision
- HPS
- KURA Strong Buy
- Analyst Count
- HPS 0
- KURA 13
- Target Price
- HPS N/A
- KURA $24.45
- AVG Volume (30 Days)
- HPS 58.4K
- KURA 1.8M
- Earning Date
- HPS 01-01-0001
- KURA 08-07-2025
- Dividend Yield
- HPS 8.62%
- KURA N/A
- EPS Growth
- HPS N/A
- KURA N/A
- EPS
- HPS N/A
- KURA N/A
- Revenue
- HPS N/A
- KURA $83,279,000.00
- Revenue This Year
- HPS N/A
- KURA $60.25
- Revenue Next Year
- HPS N/A
- KURA $155.10
- P/E Ratio
- HPS N/A
- KURA N/A
- Revenue Growth
- HPS N/A
- KURA N/A
- 52 Week Low
- HPS $11.79
- KURA $5.41
- 52 Week High
- HPS $15.40
- KURA $21.57
- Technical
- Relative Strength Index (RSI)
- HPS 59.80
- KURA 68.50
- Support Level
- HPS $14.58
- KURA $7.47
- Resistance Level
- HPS $14.70
- KURA $7.80
- Average True Range (ATR)
- HPS 0.08
- KURA 0.43
- MACD
- HPS 0.01
- KURA 0.13
- Stochastic Oscillator
- HPS 48.72
- KURA 95.26
About HPS John Hancock Preferred Income Fund III Preferred Income Fund III
John Hancock Preferred Income Fund III is a closed-end, diversified management investment company. Its investment objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve the objectives by investing a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. The portfolio composition of the company consists of the U.S. preferred securities, foreign preferred securities, common stocks, corporate bonds, and the short-term investments.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.